Notification to Clients: COVID-19 Policy Exception Statement
Salus IRB issues policy exception statement for reviewing study modifications due to COVID-19.
FDA Guidance March 2020 Clinical Trial Conduct during COVID-19
The FDA has issued the following guidance concerning Clinical Trial Conduction during the ongoing COVID-19 pandemic.
COVID-19 Instructions for Clients
Salus IRB offices are open and fully operational. Our team has the capacity to work remotely, if
necessary, and IRB meetings are conducted online. Please follow the link for additional instructions for research sites, study change considerations, IRB Approval, and IRB Notification of Study Changes